Synvista Therapeutics, Inc. Form S-8 POS March 12, 2009

As filed with the Securities and Exchange Commission on March 11, 2009

Registration No. 333-126563

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8

REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

SYNVISTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter)

Delaware 13-3304550
(State or other jurisdiction (IRS Employer of incorporation or organization) Identification Number)

221 West Grand Avenue
Montvale, New Jersey
(Address of Principal Executive Offices)

ALTEON INC. 2005 STOCK PLAN (Full title of the plan)

Noah Berkowitz, M.D., Ph.D.
President and Chief Executive Officer
Synvista Therapeutics, Inc.
221 West Grand Avenue
Montvale, NJ 07645
(201) 934-5000

(Name, address, including zip code, and telephone number, including area code, of agent for

service)

Copies to:
Megan N. Gates, Esq.
Mintz, Levin, Ferris, Glovsky & Popeo, P.C.
One Financial Center
Boston, MA 02111
(617) 542-6000

07645

(Zip Code)

DEREGISTRATION OF UNSOLD SECURITIES

On July 13, 2005, Synvista Therapeutics, Inc., formerly known as Alteon Inc. (the "Company"), filed a registration statement on Form S-8 (File No. 333-126563) (the "Registration Statement"). The Registration Statement registered a total of 5,000,000 shares of the Company's common stock, par value \$0.01 per share (the "Common Stock"), to be issued pursuant to the Company's 2005 Stock Plan. This offering has been terminated because the Company intends to deregister its Common Stock under the Securities Exchange Act of 1934, as amended. Consequently, in accordance with an undertaking made by the Company in the Registration Statement to remove from registration, by means of a post-effective amendment, any of the securities that remain unsold at the termination of the offering, the Company hereby removes from registration the securities of the Company that are registered but unsold under the Registration Statement.

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment No. 1 to its Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Montvale, State of New Jersey on March 11, 2009.

SYNVISTA THERAPEUTICS, INC.

/s/ Noah Berkowitz, M.D., Ph.D. Noah Berkowitz, M.D., Ph.D. President and Chief Executive Officer

Pursuant to the requirements of the Securities Act of 1933, this Post-Effective Amendment No. 1 to the Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

Signature	Title	Date
/s/ Noah Berkowitz, M.D., Ph.D. Noah Berkowitz, M.D., Ph.D.	President, Chief Executive Officer and Director	March 11, 2009
/s/ Wendy A. Milici Wendy A. Milici	Principal Financial Officer and Principal Accounting Officer	March 11, 2009
/s/ John F. Bedard John F. Bedard	Director	March 11, 2009
/s/ William Federici William Federici	Director	March 11, 2009
/s/ Mary C. Tanner Mary C. Tanner	Director	March 11, 2009
/s/ Wayne P. Yetter Wayne P. Yetter	Director	March 11, 2009